108 related articles for article (PubMed ID: 27372418)
1. Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization.
Wu SE; Charles HW; Park JS; Goldenberg AS; Deipolyi AR
Diagn Interv Imaging; 2017 Jan; 98(1):37-42. PubMed ID: 27372418
[TBL] [Abstract][Full Text] [Related]
2. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: Impact of Embolic Density and Residual Tumor Perfusion on Tumor Recurrence and Survival.
Ruff C; Artzner C; Syha R; Grosse U; Hoffmann R; Bitzer M; Partovi S; Horger M; Nikolaou K; Grözinger G
Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1403-1413. PubMed ID: 34021375
[TBL] [Abstract][Full Text] [Related]
4. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma.
Young S; Sanghvi T; Sharma S; Richardson C; Rubin N; Richards M; D'Souza D; Flanagan S; Golzarian J
Diagn Interv Imaging; 2022 Mar; 103(3):143-149. PubMed ID: 35115276
[TBL] [Abstract][Full Text] [Related]
5. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
6. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
[TBL] [Abstract][Full Text] [Related]
7. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
[TBL] [Abstract][Full Text] [Related]
8. [Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].
Herber SC; Otto G; Woerns M; Moench C; Kanzler S; Junginger T; Schneider J; Schuchmann M; Kummer I; Manzl N; Düber C; Pitton MB
Rofo; 2007 Mar; 179(3):289-99. PubMed ID: 17325996
[TBL] [Abstract][Full Text] [Related]
9. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
10. Microwave ablation for hepatocellular carcinoma associated with Budd-Chiari syndrome after transarterial chemoembolization: an analysis of ten cases.
Dou JP; Yu J; Han ZY; Liu FY; Cheng ZG; Liang P
Abdom Radiol (NY); 2017 Mar; 42(3):962-968. PubMed ID: 27688061
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
[TBL] [Abstract][Full Text] [Related]
13. [Transarterial chemoembolization plus computed tomography-guided percutaneous radiofrequency ablation for small hepatocellular carcinoma in special locations].
Guo YJ; Huang WS; Zhou B; Chen JW; Cai MY; Qian JS; Huang MS; Shan H; Zhu KS
Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(33):2627-30. PubMed ID: 24360041
[TBL] [Abstract][Full Text] [Related]
14. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
Bargellini I; Bozzi E; Campani D; Carrai P; De Simone P; Pollina L; Cioni R; Filipponi F; Bartolozzi C
Eur J Radiol; 2013 May; 82(5):e212-8. PubMed ID: 23332890
[TBL] [Abstract][Full Text] [Related]
15. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
16. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
17. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
18. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
